Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2006

View Archived Issues

Eisai: H1 review

In vitro activity, phase I safety of Reolysin(R) reported

Mapatumumab/chemotherapy combination feasible and active in cancer patients

Incyte reveals quarterly developments

Kinases in cardiology

Histone deacetylase inhibitors stabilize atherosclerotic plaques in macrophages

Novartis novel FAK inhibitor shows antitumor efficacy in vitro and in vivo

Multi-targeted kinase inhibition by JNJ-26483327 shows therapeutic potential in preclinical studies

Update on Exelixis oncology pipeline: Part I

In vitro studies suggest potential use of novel IKK2 inhibitor in glomerulonephritis

Genmab inlicenses MIF receptor target

VIR-201 HIV/AIDS vaccine cleared for U.S. phase II trials

Enrollment open in phase IIb study of QR-333 for diabetic peripheral neuropathy

Fodosine designated an orphan drug in Europe for T-cell ALL

Oragenics acquires iviGene

Pharmion and Nippon Shinyaku sign Japanese licensing agreement for Vidaza

Auxilium begins phase III trials for AA-4500 in Dupuytren's contracture

pSivida collaborates on transdermal drug delivery system development

Silenor yields statistically significant improvements in elderly insomnia patients

Recent patents impart new therapeutic agents for cancer

Novel antiarthritic agents described in recent patent literature

New compounds with potential use in asthma therapy reported

Disulfiram in cancer: copper-proteasome-apoptosis connection

Emerging companies showcased at BIO-Europe 2006: Alligator Bioscience

Treatment update on macular edema: snapshots of recent studies

Introgen reports on utility of NPRL2 nanoparticles in lung cancer

First launch for Grazax

Byetta approved in E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...